With your support, we have been able to fund outstanding research, leading toward cures and improved quality of life for children with cancer. Browse through more than 1,000 funded projects below.
Use the search tool to refine your results. You can also click on a heading to sort by project title, institution name, or year the grant was awarded. Click on the project title to read more information.
You can learn about ALSF's grant review process here.
ALSF Funded Research Projects
|Project Title||Institution / Principal Investigator(s)||Grant Type||Year||State|
|Natural Killer T cells with an IL-15-armored GD2-specific CAR for Children with Neuroblastoma||Baylor College of Medicine / Andras Heczey, MD||Bio-Therapeutic Impact Award||2017||Texas|
|Dissecting and Targeting the Wnt Signaling Pathway in Metastatic Osteosarcoma||Baylor College of Medicine / Jason T. Yustein, MD, PhD||Young Investigator Grants||2013||Texas|
|The Role of MiRNA Impairment in Wilms' Tumor Formation||University of Texas Southwestern Medical Center at Dallas / Kenneth Chen, MD||Young Investigator Grants||2016||Texas|
|Optimizing Engager T-cells for CD19+ Malignancies||Baylor College of Medicine / Mireya Paulina Velasquez, MD||Young Investigator Grants||2014||Texas|
|Telomeres and Telomerase in Pediatric Acute Myeloid Leukemia||Baylor College of Medicine / Maria Gramatges||Young Investigator Grants||2011||Texas|
|RNA Methylation in Metabolically Disrupted Pediatric Cancers||University of Texas Health Science Center at San Antonio / Patricia Dahia, MD/PhD||Innovation Grants||2018||Texas|
|Genetically Engineered T Cells as Therapy for Pediatric Glioma||Baylor College of Medicine / Giedre Krenciute, PhD||Young Investigator Grants||2016||Texas|
|Mechanisms of LYL1-associated T-ALL development||Baylor College of Medicine / Margaret Goodell, PhD||Innovation Grants||2012||Texas|
|STAT3 Signaling Profiles Predict Response to Chemotherapy in Pediatric AML||Baylor College of Medicine / Michele Redell, M.D./Ph.D.||Springboard Grants||2014||Texas|
|V alpha-invariant NKT cells as a novel platform for cancer immunotherapy||Baylor College of Medicine / Leonid Metelitsa, MD, PhD||Innovation Grants||2012||Texas|